Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Sees Large Decrease in Short Interest

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the target of a significant decline in short interest in February. As of February 15th, there was short interest totalling 55,500 shares, a decline of 42.2% from the January 31st total of 96,000 shares. Approximately 3.3% of the company’s shares are sold short. Based on an average trading volume of 64,900 shares, the short-interest ratio is presently 0.9 days.

Hedge Funds Weigh In On Lixte Biotechnology

A hedge fund recently bought a new stake in Lixte Biotechnology stock. Atlas Legacy Advisors LLC bought a new position in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,707 shares of the company’s stock, valued at approximately $26,000. Atlas Legacy Advisors LLC owned approximately 0.56% of Lixte Biotechnology at the end of the most recent quarter. 5.10% of the stock is currently owned by institutional investors.

Lixte Biotechnology Price Performance

LIXT traded down $0.03 on Tuesday, hitting $1.19. The company had a trading volume of 10,689 shares, compared to its average volume of 315,995. The stock has a fifty day simple moving average of $2.09 and a 200-day simple moving average of $1.95. The firm has a market capitalization of $2.67 million, a P/E ratio of -0.68 and a beta of -0.04. Lixte Biotechnology has a 52-week low of $1.17 and a 52-week high of $4.40.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.